532523:BOM
Biocon Ltd
₹351.25
arrow_upward
+0.06%(+0.20) 1H
14 Okt, 3:30:00 PTG GMT+5:30 · INR
search
Semua simbol
| Simbol | Harga | Perubahan | % Perubahan |
|---|
insights_autoMenjana cerapan popular untuk 532523...
Buka
₹352.80
Tinggi
₹352.80
Rendah
₹346.95
Permodalan Pasaran
571.07B
Purata volum
717.26K
Volum
180.12K
Dividen
0.14%
Dividen suku tahunan
₹0.12
Tarikh tanpa dividen
3 Jul 2026
Nisbah H/P
103.99
tgi 52 mgu
₹447.00
rdh 52 mgu
₹337.95
EPS
₹3.38
Syer tertunggak
600.00J
Bilangan pekerja
16K
Buka
₹352.80
Tinggi
₹352.80
Rendah
₹346.95
Permodalan Pasaran
571.07B
Purata volum
717.26K
Volum
180.12K
Dividen
0.14%
Dividen suku tahunan
₹0.12
Tarikh tanpa dividen
3 Jul 2026
Nisbah H/P
103.99
tgi 52 mgu
₹447.00
rdh 52 mgu
₹337.95
EPS
₹3.38
Syer tertunggak
600.00J
Bilangan pekerja
16K
Cerita berita
Daripada sumber web dan rakan kongsi berita
BusinessLine
·
8 jam lalu
Biocon gets launch clarity for breast cancer biosimilar after Genentech deal
Trade Brains
·
13 jam lalu
Biocon, ACC, and 4 Other Nifty 500 Stocks Trading Below RSI 30; Do You Own Any?
Equitypandit
·
18 jam lalu
Biocon Settles Patent Dispute With Genentech; Shares Down
Business Standard
·
19 jam lalu
Biocon clears patent hurdle for breast cancer biosimilar Pebrilzo
Profil
Biocon Limited is an Indian biopharmaceutical company based in Bengaluru, with U.S. headquarters in Bridgewater, New Jersey. Founded by Kiran Mazumdar-Shaw in 1978 as a partner to the Irish brewing enzyme manufacturer Biocon Biochemicals Ltd., the company manufactures generic active pharmaceutical ingredients that are sold in approximately 120 countries, including the United States and Europe. It also manufactures novel biologics, and branded drugs such as biosimilar insulins and antibodies for the Indian domestic market. Biocon's biosimilar products are also sold in both bulk and formulation forms in several emerging markets.
Biocon's formulations for the Indian market include metabolics, oncology, immunotherapy, and nephrology products. Some of Biocon's key brands in India include INSUGEN, BASALOG, BIOMAb EGFR, BLISTO, CANMAb, Evertor, TACROGRAF, ALZUMAb and KRABEVA.
Syngene International Limited is a publicly listed subsidiary of Biocon, operating in the contract research and development organization. Wikipedia
Perihal Biocon Ltd
CEOShreehas P Tambe
Pekerja16.4K
Diasaskan29 Nov 1978
Ibu pejabatBangalore, Karnataka, India
Sektor-
Laman webbiocon.com